VHH-based chimeric antigen receptor T cells against CD70 to eliminate primary and rechallenge renal cell carcinoma tumors in preclinical study.

被引：0
作者：
Jiang, Pengfei [1 ]
Xiong, Qinghui [1 ]
Wang, Haiying [1 ]
Deng, Tian [1 ]
机构：
[1] HRAIN Biotechnol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14540
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
    Ying, Zhitao
    He, Ting
    Wang, Xiaopei
    Zheng, Wen
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Ping, Lingyan
    Zhang, Chen
    Liu, Weiping
    Deng, Lijuan
    Wu, Meng
    Feng, Feier
    Leng, Xin
    Du, Tingting
    Qi, Feifei
    Hu, Xuelian
    Ding, Yanping
    Lu, Xin-an
    Song, Yuqin
    Zhu, Jun
    BMC CANCER, 2021, 21 (01)
  • [32] A preclinical study of allogeneic CD19 chimeric antigen receptor double-negative T cells as an off-the-shelf immunotherapy drug against B-cell malignancies
    Wang, Dan
    Wang, Liuyang
    Liu, Shuai
    Tong, Jianjun
    Zhu, Honglin
    Xu, Man
    Li, Xiancai
    Xiang, Zhiqiang
    Sun, Qinghua
    Wang, Hengcai
    Wang, Yuli
    Wang, Shuyang
    Yang, Liming
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (12)
  • [33] Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma
    Tu, Sanfang
    Huang, Rui
    Zhou, Xuan
    He, Yanjie
    Liang, Zhao
    Wang, Lei
    Chang, Lung-Ji
    Li, Yuhua
    BLOOD, 2018, 132
  • [34] Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
    Zhitao Ying
    Ting He
    Xiaopei Wang
    Wen Zheng
    Ningjing Lin
    Meifeng Tu
    Yan Xie
    Lingyan Ping
    Chen Zhang
    Weiping Liu
    Lijuan Deng
    Meng Wu
    Feier Feng
    Xin Leng
    Tingting Du
    Feifei Qi
    Xuelian Hu
    Yanping Ding
    Xin-an Lu
    Yuqin Song
    Jun Zhu
    BMC Cancer, 21
  • [35] Targeting T-cell Leukemia with CD5-Based Chimeric Antigen Receptor-Modified γδ T Cells
    Fleischer, Lauren C.
    Zoine, Jaquelyn T.
    Ryan, Rebecca E.
    Raikar, Sunil S.
    Doering, Christopher B.
    Spencer, H. Trent
    MOLECULAR THERAPY, 2018, 26 (05) : 57 - 57
  • [36] Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
    Haensch, Lena
    Peipp, Matthias
    Mastall, Maximilian
    Villars, Danielle
    Myburgh, Renier
    Silginer, Manuela
    Weiss, Tobias
    Gramatzki, Dorothee
    Vasella, Flavio
    Manz, Markus G.
    Weller, Michael
    Roth, Patrick
    NEURO-ONCOLOGY, 2023, 25 (11) : 2001 - 2014
  • [37] Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
    Zu, Yingling
    Ren, Quan
    Zhang, Jishuai
    Su, Hongchang
    Lu, Qiumei
    Song, Yongping
    Zhou, Jian
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [38] Universal redirection of chimeric antigen receptor T cells against solid tumors via tumor cell membrane-inserting CAR ligands
    Zhang, Angela
    CANCER RESEARCH, 2023, 83 (07)
  • [39] Gastrodin synergistically increases migration of interleukin-13 receptor a2 chimeric antigen receptor T cell to the brain against glioblastoma multiforme: A preclinical study
    Huang, Shuai
    Bai, Yue
    An, Zhijing
    Xu, Chang
    Zhang, Can
    Wang, Fang
    Zhong, Chunlong
    Zhong, Xiaosong
    PHYTOTHERAPY RESEARCH, 2023, 37 (12) : 5947 - 5957
  • [40] Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model
    Sun, Hongxing
    He, Shan
    Meng, Lijun
    Wang, Ying
    Zhang, Hanghang
    Liu, Yongnian
    Wang, Jian
    Tao, Min
    Barta, Stefan Klaus
    Al-Saleem, Essel D.
    Fung, Henry C.
    Issa, Jean-Pierre
    Zheng, Leizhen
    Zhang, Yi
    BLOOD, 2018, 132
12345